Clinique Sainte Anne

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer3 trials
• Prostate cancer3 trials
• Bladder cancer2 trials
• Endometrial cancer1 trial
• Gastric and oesophageal cancer1 trial
• Kidney cancer1 trial
• Liver and biliary tract cancer1 trial
• Lung cancer1 trial
• Metastatic breast cancer1 trial
• Multiple myeloma1 trial
• Myeloproliferative neoplasms1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 36 trials
• Phase 25 trials
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Completed7 trials
• Recruiting6 trials
• Active, not recruiting2 trials
• Terminated1 trial

Lead sponsor

• Federation Francophone de Cancerologie Digestive4 trials
• Gustave Roussy, Cancer Campus, Grand Paris3 trials
• Pfizer2 trials
• Amgen1 trial
• Centre Hospitalier Regional Et Universitaire De Brest1 trial
• and 5 more

Running trials

• Not yet recruiting

  Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

  NCT07151586· Phase 2· UNICANCER· Source

• Recruiting

  Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

  NCT07124858· Federation Francophone de Cancerologie Digestive· Source

  Contact: LOUIS MARIE DOURTHE

• Not yet recruiting

  PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma

  NCT07128290· Phase 2· Federation Francophone de Cancerologie Digestive· Source

• Recruiting

  Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms

  2024-515362-13-00· Phase 2/3· Centre Hospitalier Regional Et Universitaire De Brest· Source

• Recruiting

  Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer

  NCT06712472· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

  Contact: YOUCEF TAZI, MD

• Recruiting

  Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study

  NCT05692999· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

  NCT03819101· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Active, not recruiting

  A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

  NCT03473743· Phase 1/2· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Prostate cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

  NCT05901649· Janssen-Cilag Ltd.· Source

• Completed

  A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

  NCT04822350· Pfizer· Source

• Completed

  Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

  NCT04191616· Phase 2· Amgen· Source

• Completed

  FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

  NCT03584711· Phase 2· Federation Francophone de Cancerologie Digestive· Source

• Completed

  Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

  NCT03260894· Phase 3· Incyte Corporation· Source

• Terminated

  Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

  NCT03117972· Phase 2· Centre Hospitalier Universitaire de Besancon· Source

• Completed

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· Phase 3· Federation Francophone de Cancerologie Digestive· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source